International consensus on preliminary definitions of improvement in adult and juvenile myositis.
OBJECTIVE
To use a core set of outcome measures to develop preliminary definitions of improvement for adult and juvenile myositis as composite end points for therapeutic trials.


METHODS
Twenty-nine experts in the assessment of myositis achieved consensus on 102 adult and 102 juvenile paper patient profiles as clinically improved or not improved. Two hundred twenty-seven candidate definitions of improvement were developed using the experts' consensus ratings as a gold standard and their judgment of clinically meaningful change in the core set of measures. Seventeen additional candidate definitions of improvement were developed from classification and regression tree analysis, a data-mining decision tree tool analysis. Six candidate definitions specifying percentage change or raw change in the core set of measures were developed using logistic regression analysis. Adult and pediatric working groups ranked the 13 top-performing candidate definitions for face validity, clinical sensibility, and ease of use, in which the sensitivity and specificity were >/=75% in adult, pediatric, and combined data sets. Nominal group technique was used to facilitate consensus formation.


RESULTS
The definition of improvement (common to the adult and pediatric working groups) that ranked highest was 3 of any 6 of the core set measures improved by >/=20%, with no more than 2 worse by >/=25% (which could not include manual muscle testing to assess strength). Five and 4 additional preliminary definitions of improvement for adult and juvenile myositis, respectively, were also developed, with several definitions common to both groups. Participants also agreed to prospectively test 6 logistic regression definitions of improvement in clinical trials.


CONCLUSIONS
Consensus preliminary definitions of improvement were developed for adult and juvenile myositis, and these incorporate clinically meaningful change in all myositis core set measures in a composite end point. These definitions require prospective validation, but they are now proposed for use as end points in all myositis trials.
Rider
Lisa G
LG
National Institute of Environmental Health Sciences, NIH, Bethesda, Maryland 20892, USA. RIDER@niehs.nih.gov
Giannini
Edward H
EH
Brunner
Hermine I
HI
Ruperto
Nicola
N
James-Newton
Laura
L
Reed
Ann M
AM
Lachenbruch
Peter A
PA
Miller
Frederick W
FW
D000328:Adult; D002648:Child; D006801:Humans; D009220:Myositis; D009626:Terminology as Topic